(Q39203692)

10 September 2017

title

Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas (English)

1 reference

10 September 2017

1 reference

8

1 reference

10 September 2017

Tina Dasgupta

1

1 reference

10 September 2017

Daphne A Haas-Kogan

2

1 reference

10 September 2017

Xiaodong Yang

3

1 reference

10 September 2017

Aleksandra Olow

4

1 reference

10 September 2017

Daniel X Yang

5

1 reference

10 September 2017

Ashley Gragg

6

1 reference

10 September 2017

Lisa A Orloff

7

1 reference

10 September 2017

publication date

26 January 2013

1 reference

Investigational New Drugs

10 September 2017

published in

1 reference

10 September 2017

volume

31

1 reference

10 September 2017

issue

5

1 reference

10 September 2017

page(s)

1136-1141

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-013-9928-9

10 September 2017

exact match

0 references

cites work

Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Prognostic utility of BRAF mutation in papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

RAF antisense oligonucleotide as a tumor radiosensitizer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Clonogenic assay of cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Targeted therapy for BRAFV600E malignant astrocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-013-9928-9

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

21 January 2018

1 reference

12 December 2020

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).

1 reference

12 December 2020

Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo

1 reference

12 December 2020

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?

1 reference

12 December 2020

10.1007/S10637-013-9928-9

Identifiers

DOI

1 reference

10 September 2017

1 reference